FDA Adverse Event Injury Summary report: N

HARMONY

MDR report key: 8152571 · Received December 11, 2018

Report

Report Number
3004167969-2018-00012
Event Type
Injury
Date Received
December 11, 2018
Date of Event
November 8, 2018
Report Date
November 12, 2018
Manufacturer
ALMA LASERS LTD
Product Code
GEX
UDI-DI
17290110120433
PMA / PMN Number
K072564
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NC, US
Reporter Occupation
501

Narratives

Additional Manufacturer Narrative · 0

EXEMPTION LETTER E2013012 ALMA LTD. (MANUFACTURER) IS SUBMITTING THE REPORT ON BEHALF OF ALMA, INC. (IMPORTER). ALMA INC. (IMPORTER) HAS EVALUATED THE HANDPIECE AND FOUND THAT IT MEETS MANUFACTURER'S SPECIFICATIONS. THE SYSTEM WAS ALSO INSPECTED AND IT WAS FOUND THAT IT HAD A DAMAGED HANDPIECE CONNECTOR. THE DAMAGED HANDPIECE CONNECTOR IS NOT LIKELY TO CONTRIBUTE TO THE ADVERSE EVENT AS THE SYSTEM CANNOT BE OPERATED IN THIS CONDITION. IT APPEARS THAT THE DAMAGE TO THE HANDPIECE CONNECTOR MAY HAVE OCCURRED DURING THE TRANSIT BACK TO ALMA. PER THE FACILITY, PATIENT BURNS WERE DIAGNOSED AS SECOND AND THIRD DEGREE BURNS. AT THIS TIME NO NEW PHOTOGRAPHS OR INFORMATION IS AVAILABLE TO ASSESS THE PATIENT SKIN CONDITION. THEREFORE, ALMA LASERS IS SUBMITTING THE REPORT TO FDA IN GOOD FAITH EFFORTS. BASED ON THE INFORMATION AVAILABLE, ALMA LASERS LTD. CLINICAL DETERMINED THAT FAILURE TO PERFORM SKIN TEST AND THE NUMBER OF PULSES ADMINISTERED FOR THE PATIENT'S SKIN CONDITION WERE LIKELY EXCESSIVE CONTRIBUTING TOWARDS THIS UNTOWARD SKIN REACTION.

Description of Event or Problem · 0

THE SUSPECTED DEVICE WAS USED ON PATIENT'S LEGS BILATERALLY FOR BENIGN PIGMENTED LESIONS. THE FACILITY PROVIDED THE PATIENT WITH BIAFINE TOPICAL EMULSION AND 800 MG IBUPROFEN AS POST-TREATMENT CARE. PER THE FACILITY, THE PATIENT WAS SEEING A WOUND CARE SPECIALIST AS AN OUT-PATIENT INITIALLY BUT WAS LATER ADMITTED AS AN IN-PATIENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
992983 HARMONY MEDICAL LASER GEX ALMA LASERS LTD 540 VL/PL 17290110120433

Patients

Seq Age Sex Outcome Treatment
1 45 YR Hospitalization